InsidersTradesSigma
Palisade Bio, INC. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Palisade Bio, INC. share price and the full insider trade history of the company, a listed issuer based in United States. Shares are listed on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Palisade Bio, INC. has logged 65 reports. Market capitalisation: €364.9m. The latest transaction was filed on 8 July 2026 (Acquisition). Among the most active insiders: Finley John David. The full history is openly available.
65
Insider Decl.
0
Thresholds
€313,617
27 ops.
Buy Volume
€358,292
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Palisade Bio, INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$10.50.
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations65 total
20,000 shares@ US$2.052Common StockSEC:0001493152-26-032563:0
Ideal exit: 2 Apr 2027 (T+270)
30,000 shares@ US$2.0348Common StockSEC:0001493152-26-032563:1
Ideal exit: 3 Apr 2027 (T+270)
335,167 sharesCommon StockSEC:0001493152-26-032559:0
146,798 shares@ US$2.0664Common StockSEC:0001493152-26-032559:1
133 shares@ US$0.70Common StockSEC:0001493152-26-032559:2
131,167 sharesCommon StockSEC:0001493152-26-032561:0
51,880 shares@ US$2.0535Common StockSEC:0001493152-26-032561:1
20,000 shares@ US$1.980.011% mcap66.8% of flowCommon StockSEC:0001493152-26-032229:0
Ideal exit: 28 Mar 2027 (T+270)
10,000 shares@ US$1.980.0054% mcap33.2% of flowCommon StockSEC:0001493152-26-032229:1
Ideal exit: 29 Mar 2027 (T+270)
336,904 sharesCommon StockSEC:0001493152-26-029329:0
592,300 sharesCommon StockSEC:0001493152-26-028570:0
20,200 sharesCommon StockSEC:0001493152-26-028570:1
388 shares0Comon Stock, par value $0.01SEC:0001493152-24-047363:0
388 shares0Comon Stock, par value $0.01SEC:0001493152-24-047364:0
465 shares0Comon Stock, par value $0.01SEC:0001493152-24-023614:0
340 shares0Comon Stock, par value $0.01SEC:0001493152-24-023612:0
2,735 shares0Common Stock, par value $0.01SEC:0001493152-24-022038:0
1,622 shares0Common Stock, par value $0.01SEC:0001493152-24-022037:0
1,000 shares@ US$4.86322.0% of flowComon Stock, par value $0.01SEC:0001493152-24-021777:0
Ideal exit: 22 Feb 2025 (T+270)
1,000 shares@ US$4.814.9% of flowCommon Stock, par value $0.01SEC:0001493152-24-021431:0
Ideal exit: 18 Feb 2025 (T+270)
666 shares@ US$4.97253.4% of flowCommon Stock, par value $0.01SEC:0001493152-24-021045:0
304 shares0Common Stock, par value $0.01SEC:0001493152-24-018284:0
232 shares0Common Stock, par value $0.01SEC:0001493152-24-018282:0
5,558 shares0Common Stock, par value $0.01SEC:0001493152-24-009709:0
6,980 shares0Common Stock, par value $0.01SEC:0001493152-24-006048:0
25 of 65 declarations
About Palisade Bio, INC.
Palisade Bio, Inc. (NASDAQ: PALI) is a clinical-stage biopharmaceutical company headquartered in Carlsbad, California, in the United States and listed on the Nasdaq Capital Market. For investors, the company stands out as a highly focused development story rather than a diversified commercial biotech. Its core strategy is built around a differentiated oral prodrug platform centered on PDE4 biology, with the aim of improving tolerability, pharmacology, and convenience for patients with chronic inflammatory and fibrotic diseases. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001357459/000135745926000004/pali-20251231.htm?utm_source=openai)) The company’s lead asset is PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed to be selectively activated in the terminal ileum and colon. The logic of the program is to concentrate activity at the site of disease while limiting systemic exposure, which may help reduce the class-related CNS and gastrointestinal side effects that have historically constrained PDE4 therapies. Palisade Bio’s disclosed development focus is inflammatory bowel disease, especially ulcerative colitis and fibrostenotic Crohn’s disease, with the platform concept potentially expandable to other inflammatory and fibrotic indications. ([palisadebio.com](https://palisadebio.com/about-us-overview/?utm_source=openai)) In competitive terms, Palisade Bio fits the profile of a small-cap U.S. biotech whose valuation is driven primarily by clinical data, regulatory milestones, and funding execution. The company does not yet have a commercial product base or meaningful recurring operating revenue; instead, its investment case depends on whether PALI-2108 can demonstrate a compelling efficacy/safety profile and a clear differentiation versus existing IBD treatments. That makes the shares on the Nasdaq particularly sensitive to trial readouts, protocol updates, and capital raises. ([palisadebio.com](https://palisadebio.com/pipeline-overview/?utm_source=openai)) Recent company updates have been constructive. In 2025 and 2026, Palisade Bio reported positive Phase 1a and Phase 1b results for PALI-2108, including additional topline data in fibrostenotic Crohn’s disease and ulcerative colitis. The latest quarterly update also highlighted continued clinical progress and anticipated Phase 2 trial initiations in 2026, signaling that management is attempting to move the lead program from proof-of-concept into later-stage development. For investors in the United States-listed Nasdaq name, the story remains a classic clinical catalyst pipeline: high upside if execution continues, but also elevated binary risk typical of development-stage biotech. ([palisadebio.com](https://palisadebio.com/palisade-bio-reports-first-quarter-2026-financial-results-and-highlights-continued-clinical-progress-of-pali-2108/?utm_source=openai))
